Log in

LUDG LUDWIG ENTERPRISES, INC. OTC · United States

LUDWIG ENTERPRISES, INC. (LUDG) news

LUDWIG ENTERPRISES, INC. is a public biotech or pharmaceutical company listed on OTC under the ticker LUDG, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest LUDWIG ENTERPRISES, INC. news

We have not published a story on LUDWIG ENTERPRISES, INC. yet. When there is news, it will appear here.

LUDWIG ENTERPRISES, INC. annual financials

LineFY2025FY2024
Revenue$217
Research and development$231,593$165,621
Net income (loss)-$2.2 million-$3.0 million
Cash from operations-$644,842-$660,302
Cash and equivalents$0$217

Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $18,323, plus short-term investments of $175,000, $193,323 in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about LUDWIG ENTERPRISES, INC.

What is the ticker symbol of LUDWIG ENTERPRISES, INC.?

LUDWIG ENTERPRISES, INC. trades under the ticker LUDG on OTC.

Where is LUDWIG ENTERPRISES, INC. listed?

LUDWIG ENTERPRISES, INC. is listed on OTC.

Which country or territory is LUDWIG ENTERPRISES, INC. listed under?

Our directory records LUDWIG ENTERPRISES, INC. under United States.

Does aibio.space cover LUDWIG ENTERPRISES, INC.?

aibio.space lists LUDWIG ENTERPRISES, INC. among 2,820 public biotech companies and publishes its news here as stories appear.

Is LUDWIG ENTERPRISES, INC. profitable?

LUDWIG ENTERPRISES, INC. reported a net loss of $2.2 million for the fiscal year ended Dec 31, 2025, and used $644,842 of cash in operations, per its annual report to the SEC.

How much does LUDWIG ENTERPRISES, INC. spend on research and development?

$231,593 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does LUDWIG ENTERPRISES, INC. have?

$193,323 in cash and short-term investments at Mar 31, 2026, per its 10-Q.

Investor discussion: LUDWIG ENTERPRISES, INC.

Members talk about LUDWIG ENTERPRISES, INC. (LUDG). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at LUDWIG ENTERPRISES, INC., newest first. Each line links the filing it comes from.

  1. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source

  2. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  3. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:LUDG on TradingView.

Listing details

LUDWIG ENTERPRISES, INC. is a public biotech or pharmaceutical company listed on OTC under the ticker LUDG, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
LUDWIG ENTERPRISES, INC.
Ticker
LUDG
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.